Alpha 2.0
Login Register
» Authors » Peter Blanken

Peter Blanken

Explore the profile of Peter Blanken including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 690
Followers 0
Related Specialties
Psychiatry
Pharmacology
General Medicine
Top 10 Co-Authors
Wim van den Brink
Jan M van Ree
Vincent M Hendriks
Vincent Hendriks
Andre I Wierdsma
Matthew Randesi
Ernst L Noordraven
Mary Jeanne Kreek
Cornelis L Mulder
Mascha Nuijten
Published In
Drug Alcohol Depend
BMC Psychiatry
Addiction
Eur Addict Res
Pharmacogenomics
Affiliations
Soon will be listed here.
Recent Articles
1.
Direct and Indirect Exposure to Trauma, Posttraumatic Stress Disorder Symptoms, and Poor Subjective Sleep Quality in Patients with Substance Use Disorder
Ten Holt J, van Emmerik A, Blanken P, Borgdorff J, Ten Holt P, Kok R, et al.
Psychiatry Clin Psychopharmacol . 2024 May; 32(3):188-195. PMID: 38766672
Background: Despite the frequent co-occurrence of posttraumatic stress disorder and substance use disorder, screening for trauma exposure and posttraumatic stress disorder symptoms is not a routine practice in substance use...
2.
Accuracy of the Depression, Anxiety and Stress Scale (DASS-21) for Screening on Comorbid Internalizing Disorders among Youth in Substance Use Disorder Treatment
Moska C, Goudriaan A, Blanken P, Hendriks V
Eur Addict Res . 2023 Oct; 29(6):385-393. PMID: 37848011
Introduction: Major depression, anxiety disorders, and post-traumatic stress disorder (PTSD) are among the most prevalent comorbid mental disorders in youth addiction treatment. Hence, screening for these internalizing disorders should be...
3.
Systematic Client Feedback in Youth Mental Health and Addiction Care: A Controlled Study Comparing Two Treatment Cohorts
van Benthem P, Spijkerman R, Blanken P, Boon A, Vermeiren R, Hendriks V
Eur Addict Res . 2023 Jan; 29(1):52-62. PMID: 36649692
Introduction: We investigated the value of systematic client feedback in youth mental health and addiction care. In the present study, we examined whether a client feedback intervention would result in...
4.
The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review
van Amsterdam J, Blanken P, Spijkerman R, van den Brink W, Hendriks V
Alcohol Alcohol . 2022 Sep; 57(6):768-775. PMID: 36085572
Aim: To explore whether combined interventions i.e. psychotherapeutic plus psychosocial interventions are more effective than monotherapies in the treatment of alcohol use disorders. Methods: Systematic review of the results of...
5.
Youth in transition: Study protocol of a prospective cohort study into the long-term course of addiction, mental health problems and social functioning in youth entering addiction treatment
Moska C, Goudriaan A, Blanken P, van de Mheen D, Spijkerman R, Schellekens A, et al.
BMC Psychiatry . 2021 Dec; 21(1):605. PMID: 34863131
Background: Substance use disorders (SUDs) are prevalent in the general population, tend to follow a chronic course, are associated with many individual and social problems, and often have their onset...
6.
Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials
Moazen-Zadeh E, Ziafat K, Yazdani K, Kamel M, Wong J, Modabbernia A, et al.
Am J Drug Alcohol Abuse . 2021 Mar; 47(3):280-304. PMID: 33780647
: There is a knowledge gap in systematic reviews on the impact of opioid agonist treatments on mental health.: We compared mental health outcomes between different opioid agonist treatments and...
7.
Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users
Yuferov V, Butelman E, Randesi M, van den Brink W, Blanken P, van Ree J, et al.
Neuropsychiatr Dis Treat . 2021 Mar; 17:659-670. PMID: 33658787
Introduction: A functional tandem repeat polymorphism in the promoter of the serotonin transporter (SERT) gene (SLC6A4) has been studied for association to neuropsychiatric conditions, including substance use disorders. Short (S)...
8.
Further evidence for the association of ,  and  variants with opioid dependence
Randesi M, Levran O, van den Brink W, Blanken P, van Ree J, Ott J, et al.
Pharmacogenomics . 2020 Aug; 21(13):903-917. PMID: 32757697
Heroin addiction is a chronic, relapsing disease that has genetic and environmental, including drug-induced, contributions. Stress influences the development of addictions. This study was conducted to determine if variants in...
9.
A dual perspective on first-session therapeutic alliance: strong predictor of youth mental health and addiction treatment outcome
van Benthem P, Spijkerman R, Blanken P, Kleinjan M, Vermeiren R, Hendriks V
Eur Child Adolesc Psychiatry . 2020 Mar; 29(11):1593-1601. PMID: 32157389
We investigated the potential role of first-session therapeutic alliance ratings to serve as an early marker of treatment outcome in youth mental health and addiction treatment. The present study is...
10.
Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial
Blanken P, Nuijten M, van den Brink W, Hendriks V
Addiction . 2020 Jan; 115(5):917-923. PMID: 31908066
Background And Aims: Sustained-release (SR) formulations of dexamphetamine and mixed amphetamine salts have shown positive effects in the treatment of patients with a cocaine use disorder. We previously demonstrated the...